Beyfortus safety watch: 3,000 korean kids monitored for RSV protection

NCT ID NCT07200206

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks the safety of Beyfortus (Nirsevimab) in up to 3,000 Korean children under 24 months who receive the shot to prevent RSV. Researchers will monitor for side effects and serious events over 180 days. It is a real-world safety check, not a test of how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Nirsevimab (Beyfortus), a monoclonal antibody injection

What this could lead to

If successful, this study will confirm that Beyfortus is safe for preventing RSV in Korean children, supporting its widespread use.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove effectiveness. Rare side effects may still emerge.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nam Seung Woo Pediatric: 4100007

    RECRUITING

    Hwaseong-si, Gyeonggi-do, 18478, South Korea